Cargando…

Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date

Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem; along with medication‐induced (medication‐overuse) headache, it is the third‐leading cause of disability worldwide. Currently, its therapeutic management remains unsatisfactory for several reasons; up...

Descripción completa

Detalles Bibliográficos
Autores principales: Pellesi, Lanfranco, Guerzoni, Simona, Pini, Luigi Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697612/
https://www.ncbi.nlm.nih.gov/pubmed/28409893
http://dx.doi.org/10.1002/cpdd.345
_version_ 1783280650084679680
author Pellesi, Lanfranco
Guerzoni, Simona
Pini, Luigi Alberto
author_facet Pellesi, Lanfranco
Guerzoni, Simona
Pini, Luigi Alberto
author_sort Pellesi, Lanfranco
collection PubMed
description Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem; along with medication‐induced (medication‐overuse) headache, it is the third‐leading cause of disability worldwide. Currently, its therapeutic management remains unsatisfactory for several reasons; up to 40% of migraineurs are eligible for prophylactic treatment, but there are issues of efficacy, safety, and adherence. In recent years the evidence on the role of calcitonin gene‐related peptide (CGRP) in migraine pathophysiology has been consolidated, so new and promising treatments for migraine pain and its possible prevention have been developed. The following review reports the results of the clinical trials conducted so far with each of the new monoclonal antibodies targeting CGRP or its receptor, with particular reference to safety, tolerance, and efficacy in migraine prevention. Moreover, the pharmacological characterization and further developments of each monoclonal antibody are reported, based on current knowledge.
format Online
Article
Text
id pubmed-5697612
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-56976122017-11-28 Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date Pellesi, Lanfranco Guerzoni, Simona Pini, Luigi Alberto Clin Pharmacol Drug Dev Review Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem; along with medication‐induced (medication‐overuse) headache, it is the third‐leading cause of disability worldwide. Currently, its therapeutic management remains unsatisfactory for several reasons; up to 40% of migraineurs are eligible for prophylactic treatment, but there are issues of efficacy, safety, and adherence. In recent years the evidence on the role of calcitonin gene‐related peptide (CGRP) in migraine pathophysiology has been consolidated, so new and promising treatments for migraine pain and its possible prevention have been developed. The following review reports the results of the clinical trials conducted so far with each of the new monoclonal antibodies targeting CGRP or its receptor, with particular reference to safety, tolerance, and efficacy in migraine prevention. Moreover, the pharmacological characterization and further developments of each monoclonal antibody are reported, based on current knowledge. John Wiley and Sons Inc. 2017-04-14 2017 /pmc/articles/PMC5697612/ /pubmed/28409893 http://dx.doi.org/10.1002/cpdd.345 Text en © 2017 The Authors. Clinical Pharmacology in Drug Development published by Wiley Periodicals, Inc. on behalf of The American College of Clinical Pharmacology This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Review
Pellesi, Lanfranco
Guerzoni, Simona
Pini, Luigi Alberto
Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
title Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
title_full Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
title_fullStr Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
title_full_unstemmed Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
title_short Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
title_sort spotlight on anti‐cgrp monoclonal antibodies in migraine: the clinical evidence to date
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697612/
https://www.ncbi.nlm.nih.gov/pubmed/28409893
http://dx.doi.org/10.1002/cpdd.345
work_keys_str_mv AT pellesilanfranco spotlightonanticgrpmonoclonalantibodiesinmigrainetheclinicalevidencetodate
AT guerzonisimona spotlightonanticgrpmonoclonalantibodiesinmigrainetheclinicalevidencetodate
AT piniluigialberto spotlightonanticgrpmonoclonalantibodiesinmigrainetheclinicalevidencetodate